Overview of AKR1C3: Inhibitor Achievements and Disease Insights
- PMID: 32463235
- DOI: 10.1021/acs.jmedchem.9b02138
Overview of AKR1C3: Inhibitor Achievements and Disease Insights
Abstract
Human aldo-keto reductase family 1 member C3 (AKR1C3) is known as a hormone activity regulator and prostaglandin F (PGF) synthase that regulates the occupancy of hormone receptors and cell proliferation. Because of the overexpression in metabolic diseases and various hormone-dependent and -independent carcinomas, as well as the emergence of clinical drug resistance, an increasing number of studies have investigated AKR1C3 inhibitors. Here, we briefly review the physiological and pathological function of AKR1C3 and then summarize the recent development of selective AKR1C3 inhibitors. We propose our viewpoints on the current problems associated with AKR1C3 inhibitors with the aim of providing a reference for future drug discovery and potential therapeutic perspectives on novel, potent, selective AKR1C3 inhibitors.
Similar articles
-
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.Eur J Med Chem. 2018 Apr 25;150:930-945. doi: 10.1016/j.ejmech.2018.03.040. Epub 2018 Mar 16. Eur J Med Chem. 2018. PMID: 29602039
-
Type 5 17-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3) inhibition and potential anti-proliferative activity of cholest-4-ene-3,6-dione in MCF-7 breast cancer cells.Steroids. 2020 Jul;159:108638. doi: 10.1016/j.steroids.2020.108638. Epub 2020 Mar 21. Steroids. 2020. PMID: 32209376
-
In silico study of novel alpha tocopheroids as effective inhibitors of aldo-keto reductase 1c3 (AKR1C3) enzyme.J Biomol Struct Dyn. 2024 Sep;42(15):7715-7729. doi: 10.1080/07391102.2023.2241543. Epub 2023 Aug 3. J Biomol Struct Dyn. 2024. PMID: 37534497
-
Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. doi: 10.1080/13543776.2017.1379503. Epub 2017 Sep 19. Expert Opin Ther Pat. 2017. PMID: 28895472 Free PMC article. Review.
-
AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.Mol Cell Endocrinol. 2019 Jun 1;489:82-91. doi: 10.1016/j.mce.2018.07.002. Epub 2018 Sep 19. Mol Cell Endocrinol. 2019. PMID: 30012349 Free PMC article. Review.
Cited by
-
Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis.PLoS One. 2024 Jan 16;19(1):e0297260. doi: 10.1371/journal.pone.0297260. eCollection 2024. PLoS One. 2024. PMID: 38227591 Free PMC article.
-
Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader.Commun Chem. 2024 Apr 29;7(1):95. doi: 10.1038/s42004-024-01177-4. Commun Chem. 2024. PMID: 38684887 Free PMC article.
-
AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer Applications.ACS Med Chem Lett. 2024 Jul 3;15(8):1269-1278. doi: 10.1021/acsmedchemlett.4c00150. eCollection 2024 Aug 8. ACS Med Chem Lett. 2024. PMID: 39140045 Free PMC article.
-
GATA6 Facilitates Progression of Intervertebral Disc Degeneration by Regulating Ferroptosis via Targeting TLR2/AKR1C3.Int J Biol Sci. 2025 Jan 13;21(3):1174-1186. doi: 10.7150/ijbs.102776. eCollection 2025. Int J Biol Sci. 2025. PMID: 39897029 Free PMC article.
-
Coumarin-Based Aldo-Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors.ChemMedChem. 2024 Nov 4;19(21):e202400081. doi: 10.1002/cmdc.202400081. Epub 2024 Sep 16. ChemMedChem. 2024. PMID: 38976686
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical
Molecular Biology Databases
Miscellaneous